Table 2:
Pathways altered by PCB126 treatment of preadipocytes at the 9-hour timepoint (all significant, Fdr≤0.05).
| Pathway | pv_fdr |
|---|---|
| Cytokine-cytokine receptor interaction | 0.000213 |
| MAPK signaling pathway | 0.000213 |
| Rheumatoid arthritis | 0.001351 |
| Osteoclast differentiation | 0.002083 |
| AGE-RAGE signaling pathway in diabetic complications | 0.00959 |
| Pathways in cancer | 0.011362 |
| Amoebiasis | 0.014754 |
| Complement and coagulation cascades | 0.015962 |
| NF-kappa B signaling pathway | 0.017713 |
| Ovarian steroidogenesis | 0.017713 |
| Bladder cancer | 0.028612 |
| TGF-beta signaling pathway | 0.036269 |
| Ras signaling pathway | 0.037673 |
| Leishmaniasis | 0.039832 |
| MicroRNAs in cancer | 0.04307 |
| Cholesterol metabolism | 0.043771 |
| Inflammatory bowel disease | 0.043771 |
| Hematopoietic cell lineage | 0.043771 |
| Fluid shear stress and atherosclerosis | 0.04661 |
| Neuroactive ligand-receptor interaction | 0.04661 |